Mosliciguat cut pulmonary vascular resistance by 20 percent in Roivant’s Phase 2 PHocus trial, a result that now sends the once-daily inhaled drug directly into a Phase 3 program called PHrontier. The PVR result matters because it is the mechanistic signature of meaningful hemodynamic benefit in PH-ILD, a condition where the lung vasculature tightens as fibrosis advances and where existing approved options remain limited to treprostinil-based inhaled therapies such as Tyvaso.
The PHocus data, presented at the European Respiratory Society Congress on September 8, also showed improvement in six-minute walk distance. What makes that worth noting is the mechanism behind it: mosliciguat is an sGC activator, not an sGC stimulator. The distinction is pharmacologically real. In PH-ILD, oxidative stress depletes the heme cofactor from soluble guanylate cyclase, leaving the enzyme unresponsive to nitric oxide. An sGC stimulator requires some heme-bound enzyme to work; an activator targets the heme-free form directly. Whether that mechanistic fit translates to a clinical edge over existing options is exactly what PHrontier is designed to answer.
Roivant designed PHrontier as a Phase 3 trial in PH-ILD patients, though the company has not yet disclosed enrollment targets, primary endpoints, or a timeline for completion. The Phase 2 result gives the program a clear rationale for proceeding, but the path from hemodynamic signal to a label is still long. Regulatory agencies in PH typically want to see mortality or hospitalization data, and a trial powered for those outcomes takes years to complete and requires a much larger patient population than a Phase 2 hemodynamic study.
The commercial stakes depend almost entirely on what PHrontier’s endpoints look like. If Roivant pursues a six-minute walk distance primary endpoint, approval could come faster but payer uptake will be harder to secure against an established treprostinil standard. If the trial is powered for clinical worsening or survival, the timeline stretches but the value proposition sharpens. The endpoint choice, once Roivant discloses the PHrontier protocol, will tell you more about this program’s commercial ceiling than any Phase 2 number.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
